Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part)

BACKGROUND: Recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M-SCCHN) overexpresses αvβ5 integrin. Cilengitide selectively inhibits αvβ3 and αvβ5 integrins and is investigated as a treatment strategy. PATIENTS AND METHODS: The phase I/II study ADVANTAGE evaluated cilengiti...

Descripción completa

Detalles Bibliográficos
Autores principales: Vermorken, J. B., Peyrade, F., Krauss, J., Mesía, R., Remenar, E., Gauler, T. C., Keilholz, U., Delord, J. P., Schafhausen, P., Erfán, J., Brümmendorf, T. H., Iglesias, L., Bethe, U., Hicking, C., Clement, P. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3933250/
https://www.ncbi.nlm.nih.gov/pubmed/24567516
http://dx.doi.org/10.1093/annonc/mdu003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3933250/
https://www.ncbi.nlm.nih.gov/pubmed/24567516
http://dx.doi.org/10.1093/annonc/mdu003

Ejemplares similares